Skip to main content

Search
Profile

Bonnie W. Ramsey, MD

|
Bonnie W. Ramsey, MD

Pulmonary and Sleep Medicine

On staff since July 1980

Children's Title: Director, Center for Clinical and Translational Research; Associate Director, Pediatric Clinical Research Center

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

"I became involved in CF research because of my mentor, Arnie Smith, who was devoted to understanding the optimal antibiotic treatments for CF lung disease. Together, we developed TOBI, an inhaled form of the antibiotic tobramycin. Soon after the drug was approved as a commercial product, I happened to be riding a hospital elevator with one of my patients and her mom. The mother turned to me and said, "I want you to know that you and the TOBI you helped develop have changed my childs and our familys lives. We no longer have to live in the hospital. My daughter is now at home and able to be a normal child. Thank you.""

Making a Difference

  • Possible Secret Revealed

    A discovery about how Pseudomonas interacts with Staphylococcus points the way to understanding its drug resistance and defeating chronic lung infections.... cont.

Recommendations

JimCamano Island, WA01.25.11
Watched the TV Show about Dr. Ramsey & Dr. Smith's work on C.F. I am touched by your science but more by your efforts and want to say how wonderful you both are to commit your life's work to such a worthy cause. Nicely done. Jim S....Camano Island
Recommend Dr. Bonnie Ramsey

Overview

Board Certification(s)
Pediatric Pulmonology
Pediatrics
Medical/Professional School
Harvard Medical School, Boston
Residency
Pediatrics, Children's Hospital Boston, Boston
Clinical Interests

Cystic fibrosis

Research Focus Area

Translational Research, Cystic Fibrosis

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
Seattle's Top DocSeattle Met Magazine 2013
Seattle Magazine Top Doctor - 2012Seattle Magazine Top Doctor - 2012Seattle Magazine 2012
U.S. News Top DoctorU.S. News and World Report 2012
Inventor of the YearUniversity of Washington 2009
"Guide to America's Top Pediatricians"Consumer's Research Council of America 2009

Publications

A pipeline of therapies for cystic fibrosis.
Seminars in respiratory and critical care medicine , 2009 Oct: 611-26
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemporary clinical trials , 2009 May: 256-68
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
The Journal of pediatrics , 2009 Feb: 183-8
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan: 66-70
Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
American journal of respiratory and critical care medicine , 2007 Aug 15: 362-9
Advancing outcome measures for the new era of drug development in cystic fibrosis.
Proceedings of the American Thoracic Society , 2007 Aug 1: 370-7
Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?
Proceedings of the American Thoracic Society , 2007 Aug 1: 367-9
Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis.
Proceedings of the American Thoracic Society , 2007 Aug 1: 359-63
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Pediatric pulmonology , 2007 Jul: 610-23
Association between pulmonary function and sputum biomarkers in cystic fibrosis.
American journal of respiratory and critical care medicine , 2007 Apr 15: 822-8
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
Molecular microbiology , 2007 Apr: 512-33
Laboratory parameter profiles among patients with cystic fibrosis.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2007 Apr: 117-23
Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
Proceedings of the National Academy of Sciences of the United States of America , 2006 Dec 26: 19890-5
Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials.
Contemporary clinical trials , 2006 Dec: 561-70
Appropriate compensation of pediatric research participants: thoughts from an Institute of Medicine committee report.
The Journal of pediatrics , 2006 Jul: S15-9
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
Proceedings of the National Academy of Sciences of the United States of America , 2006 May 30: 8487-92
Clinical trial participants compared with nonparticipants in cystic fibrosis.
American journal of respiratory and critical care medicine , 2006 Jan 1: 98-104
Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis.
Environmental microbiology , 2003 Dec: 1341-9
Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.
Current opinion in pulmonary medicine , 2003 Nov: 492-7
Pathophysiology and management of pulmonary infections in cystic fibrosis.
American journal of respiratory and critical care medicine , 2003 Oct 15: 918-51
To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa?
American journal of respiratory and critical care medicine , 2002 Oct 1: 906-7
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
Chest , 2002 Jul: 219-26

Research Funding

Grant TitleGrantorAmountAward Date
Optimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter Randomized Trial Clinical Coordinating CenterNIH/NHLBISept. 15, 2013
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS)Cystic Fibrosis Foundation TherapeuticsOct. 1, 2012
Baby Observational and Nutritional Study of Cystic Fibrosis (BONUS)NIH/NIDDKAug. 3, 2012
Institute for Translational Health SciencesNIHJune 1, 2012
Molecular Biology of Cystic FibrosisCystic Fibrosis FoundationOct. 1, 2011
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS)NIH/NHLBIAug. 1, 2011
Early Intervention in CF Exacerbation (eICE Study)Cystic Fibrosis Foundation TherapeuticsAug. 1, 2011
Infant Nutrition Study of Newborns with Cystic FibrosisCystic Fibrosis Foundation TherapeuticsFeb. 1, 2011
Newly Acquired MRSA Eradication ProtocolCystic Fibrosis Foundation TherapeuticsSept. 1, 2010
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisNIH/NIDDKJuly 6, 2010
Early Intervention in Pulmonary Exacerbation in CFNIH/NHLBIJuly 1, 2010
EPIC Observational StudyCystic Fibrosis Foundation TherapeuticsApril 1, 2009
Therapeutics Development Network Coordinating CenterCystic Fibrosis Foundation TherapeuticsApril 1, 2003

Primary Office

Seattle Children's
OC.7.726 - Cystic Fibrosis Clinic
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2024

Additional Offices

Seattle Children's Research Institute
CW8-5B Center for Clinical and Translational Research
2001 Eighth Ave
Seattle , WA 98121
206-884-7591

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options